MODERATE
57
The Alpha Score is an informational signal based on public SEC fillings. It is not investment advice.
CEOJOURNAL SIGNAL SUMMARY·GENERATED FROM PUBLIC SEC FILINGS
Robert B Ford made an open-market purchase of Abbott Laboratories on 2026-01-23, investing approximately $2,013,967. This is a CEOJournal signal summary placeholder — full narrative pending Claude Haiku enrichment.
Summary based on Form 4 filings and DEF 14A proxy data. Not investment advice. Updated on new filing activity.
Score Components
COMPOSITE ALPHA SCORE
57
Score calculated from open-market purchases only; 10b5-1 preplanned trades excluded; not investment advice.
OPPORTUNISM
Proxy from ownership-change magnitude. Real Opportunism signal will use %52W proximity once price data is in pipeline.
CONVICTION
Log-scaled from trade size. Real Conviction signal will use trade $ ÷ total compensation once DEF 14A data is in pipeline.
PATTERN
Placeholder — 90-day qualifying buy count requires historical Form 4 scrapes (Phase 2).
CLUSTER
Count of other insiders buying the same ticker in our current dataset window.
TRACK RECORD
Placeholder — executive tenure × prior buy P&L requires historical price tracking (Phase 2).
FORM 4 TRANSACTION HISTORYSOURCE: SEC EDGAR
| DATE | TRANSACTION TYPE | CODE | SHARES | PRICE | TOTAL VALUE | 10b5-1 | SCORE |
|---|---|---|---|---|---|---|---|
| Jan 23, 2026 | Open-Market Purchase | P | 18,800 | $107.13 | $2,013,967 | N/A | 57 |
Data sourced from SEC EDGAR Form 4 filings, updated within 24 hours.
Only transaction code P (open-market purchase) qualifies for Alpha Score calculation.
Only transaction code P (open-market purchase) qualifies for Alpha Score calculation.
EXECUTIVE PROFILE
Robert B Ford
COB, CEO
Robert B. Ford has served as Chairman of the Board and Chief Executive Officer of Abbott Laboratories since December 2021. He was President and Chief Executive Officer of Abbott from 2020 to 2021 and previously held the position of President and Chief Operating Officer from 2018 to 2020. Mr. Ford has held various leadership roles across Abbott’s Diagnostics, Nutrition, and Diabetes Care businesses since joining the company in 1996.
EDUCATION
Pending DEF 14A enrichment.
BOARD SEATS
Pending DEF 14A enrichment.
COMPENSATION & OWNERSHIP ·SOURCE: DEF 14A PROXY
ANNUAL BASE SALARY
$1,500,000
TOTAL COMPENSATION
$24,198,660
SHARES HELD
469,508
EST. HOLDINGS VALUE
$40.19M
as of May 30, 2026 close
Summary based on Form 4 filings and DEF 14A proxy data. Not investment advice. Updated on new filing activity.
RELATED SIGNALS